Check out the latest news and information from the Foundation by liking us on Facebook!
A Phase I trial shows promising results for resiquimod gel in resolving lesions from cutaneous T-cell lymphoma (CTCL). The treatment caused disease regression, eradicated malignant T cells, and enhanced T cell effector function in 12 patients with stages IA to IIA disease. The clinical trial was conducted by researchers at the Perelman School of Medicine at the University of Pennslyvania and was co-led by Rachael Clark, MD, PhD, Associate Professor of Dermatology at Harvard Medical School; Alain Rook, MD, Professor of Dermatology and Director of the Cutaneous Lymphoma Program at Penn Medicine; and Joel M. Gelfand, MD, MSCE, Associate Professor of Dermatology and Medical Director of the Clinical Studies Unit at Penn Medicine.
Visit the following websites to read more about the clinical trial:
Early Results Promising for Topical Gel Treatment for CTCL (Online First) from Oncology Times
The 2015 summer issue of the Stanford Medicine Magazine featured an excellent article about cutaneous lymphoma, including explanations of the disease and highlighting total skin electron radiation and stem cell transplant treatments.
Click here to read the article republished with permission by Stanford Medicine Magazine.
This annual scientific meeting provides a forum for researchers, scientists and clinicians from around the world to come together to share updates and latest findings related to the biology of T-cell lymphoma as well as information about treatment options using existing therapies along with new therapies on the horizon.
Although the meeting covers all T-cell lymphomas, there were several presentations specific to cutaneous T-cell lymphoma and posters presented by experts in the field. Drs. Pierluigi Porcu, Youn Kim, Madeleine Duvic, Christiane Querfeld and Miles Prince were among the cutaneous lymphoma presenters.
The major take-away from this meeting was research to understand the molecular basis of T-cell lymphomas is ongoing and is essential to help ensure that new drugs and other therapies being developed specifically target the different types of T-cell lymphomas.
Susan Thornton, CLF's CEO, attended the Forum on behalf of the Foundation. Click here to read her highlights from the Forum.
Marianne Tawa, RN, NP, of the Center for Cutaneous Oncology at Dana Farber, has been recognized with a DAISY Award, a quarterly honor given to an extraordinary member of the nursing department. Tawa received the award during a surprise ceremony on Feb. 4. Marianne is the Vice President of the Cutaneous Lymphoma Foundation's Board of Directors.
Tawa's nomination for the award came from Betsy Doucette, whose husband, Paul, was treated for cutaneous T-cell lymphoma. In her nomination, Doucette highlighted Tawa's constant support throughout her husband's seven years of treatment.
"Marianne gave Paul such thorough, thoughtful, and compassionate care and friendship through the years, and she was the source of strength and encouragement he needed to fight his battles," Betsy says. "Paul's entire family and I are deeply grateful."
Dana-Farber is one of approximately 1,500 hospitals that participate in the DAISY Award program. The DAISY Foundation (Diseases Attacking the Immune System) established the award in memory of J. Patrick Barnes, whose parents created the foundation in Patrick's memory after experiencing firsthand the skills, care, and compassion of nurses.
(Article copied with permission from the Dana Farber's "Inside the Institute" newsletter.)